BrainCool AB (publ) receives order for one hundred (100) treatments of RhinoChill™ in Freiburg
BrainCool has signed a new sales agreement with the University hospital of Freiburg for a minimum of 100 treatments due for delivery before October 2020, of which the first 40 will be delivered this week. The product has now been fully implemented as standard treatment in the University Hospital's "Standard Operating Procedures" (SOP) for cardiac arrest patients.
At a satellite meeting during the German Intensive Care meeting in Hamburg between the 4thand 6thof December (DIVI 2019), the University hospital of Freiburg will present its updated SOP to the core leading key opinion leaders and clinics in Germany. Furthermore, BrainCool's clinical work in both cardiac arrest and thrombectomy will be presented at a hypothermia meeting in Berlin in November, which is a satellite meeting organized by one of our competitors.
CEO Martin Waleij comments;
- BrainCool continues to launch RhinoChill™ in the German market, in close collaboration with German users and key opinion leaders. During November, a number of educational and training sessions will be conducted with emergency medicine physicians and ambulance teams in Halle to implement RhinoChill™ on a larger scale.
- A close collaboration with these clinics will lay the foundation for establishing the product in Germany. We now work closely with nine hospitals that have applied for reimbursement, within the fast track NUB program (Neue Untersuchungs- und Behandlungsmethoden) representing new examination and treatment methods. The intention is to further implement the method and increase sales, as well as creating additional evidence for supporting claims in relation to insurance coverage.
University of Freiburg is one out of eight certified Cardiac Arrest Centers in Germany, certified by the Germany Resuscitation Council (GRC) with the mission of improving survival and neurological outcome for this patient group. GRC is also responsible for the German guidelines in hypothermia, which is expected to be updated and published during 2020.
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.
For more information about BrainCool’s application to be included in the NUB system:
https://spotlightstockmarket.com/en/market-overview/nyheter/nyhets-artikel/?id=53025&publisher=370
For more information about GRC and the certification of Cardiac Arrest Centers:
https://www.grc-org.de/grc-arbeitsgruppen/4-1-Cardiac-Arrest-Center